Synnerva

Company Overview

Snapshot

Founded in July 2019 by Vladimir Ritter, Synnerva operated with 1–10 employees. The company raised $500,000 across one funding round from one investor. In March 2024, Synnerva ceased operations.

Business overview

Synnerva was an early-stage pharmaceutical company focused on developing and commercializing proprietary central nervous system (CNS) drug compositions. The company's core technology involved a platform designed to significantly reduce effective drug doses and eliminate side effects by combining generic, FDA-approved APIs with stimulators of vagal afferents. This method aimed to enhance the therapeutic effects of CNS drugs like levodopa for Parkinson's disease, morphine for pain, and valproate for epilepsy, without increasing side effects. Synnerva operated within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development industries.

Company Intelligence Q&A

What was Synnerva's operational status as of March 2024?

As of March 2024, Synnerva ceased to operate, transitioning to a non-active status.

Who founded Synnerva and when?

Synnerva was founded in July 2019 by Vladimir Ritter, who also served as CEO and CTO.

What was Synnerva's primary focus in drug development?

Synnerva focused on developing proprietary central nervous system (CNS) drug compositions designed to reduce effective doses and eliminate side effects for conditions such as Parkinson's disease, pain, and epilepsy.

How much capital did Synnerva raise?

Synnerva raised $500,000 in a Seed round from NGT3.

What was the core mechanism of Synnerva's drug development platform?

Synnerva's method was based on combining generic, FDA-approved active pharmaceutical ingredients (APIs) with stimulators of vagal afferents, leading to synergistic enhancement of therapeutic effects without increased side effects.